English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  Items with full text/Total items : 92429/122733 (75%)
Visitors : 26429338      Online Users : 155
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/59992

    Title: 從全球疫苗產業趨勢探討我國預防接種的政策發展
    From the prospect of world vaccine market in analyzing Taiwan vaccine policy
    Authors: 周芳君
    Contributors: 陳桂恆
    Keywords: 疫苗產業
    Vaccine Industry
    Vaccine market
    Vaccine policy
    Date: 2010
    Issue Date: 2013-09-04 11:17:13 (UTC+8)
    Abstract: 全球疫苗市場85%是五大疫苗廠Sanofi Pasteur、MSD、GSK、Pfizer及Novartis所寡占。跟隨著研發技術發展、持續的疫苗政策、疾病地區化、公衛防治的提升,極大的市場需求,加速疫苗上市持續帶動疫苗產業成長。疫苗的預防接種是防治傳染病,最直接及最具經濟效益的投資,也是國家防疫能力的展現。本研究主要目的為彙整全球疫苗產業總體產業環境現況,探討影響全球疫苗產業發展之關鍵因素及我國疫苗政策發展。
    本研究的結論 (1)寡占的疫苗產業及疫苗產業地區化的發展趨勢,是影響未來全球疫苗產業及我國疫苗產業發展之關鍵因素。(2)財源籌集制度會影響我國疫苗政策的擬定。(3)疫苗受害救濟機制與持續教育是疫苗政策推動必要之輔助制度。(4)提升疫苗產業成為國家經濟產業,是突破法規鴻溝及研發速度的產業扶植手段之一。
    Over 85% of vaccine market was controlled by top 5 vaccine manufactures: Sanofi Pasteur, MSD, GSK, Pfizer, and Novartis. Nowadays, research and development technology are advancing; vaccine policies are continued; diseases are regionalized; public health control and prevention are increased. Thus, an extreme market demand resulted and expedited the introduction of vaccines to the markets, driving the ongoing growth of the vaccine market. Vaccination is the most direct and cost-effective investment against infectious diseases and also the demonstration of a country’s ability to against the disease outbreak. The purpose of this study was to summarize the trend of the vaccine market and explore key factors affecting the development of the global vaccine market and vaccine policy in Taiwan.
    This study was carried out mainly through documentation method and in depth interview case study. Documentation method included the collection and summary of secondary data while the interview case study was to interview the experts who were involved in the formation of vaccine policy and promotion.
    Conclusions of this study are:(1)The top 5 vaccine manufactures and vaccine industry regionalization are the key factors affecting the development of the vaccine market across the world as well as Taiwan in the future;(2)The vaccine financing affects the formulation of vaccine policy in Taiwan;(3)The vaccine injury compensation program and continuing education as auxiliary systems are necessary mechanisms for the vaccine policy promotion;and (4)Promoting the vaccine industry to the national economic industry level is one of the ways to amend regulatory gaps and advance R&D speed for the benefit of the industry.
    Reference: 一、英文部份
    1.Andrusa, Jon Kim (2008), Introduction of Human Papillomavirus Vaccines into Developing Countries -International Strategies for Funding and Procurement. Vaccine 26S, K87–K92
    2.Archibugi, Daniele. Bizzarri, Kim. (2004), Kim Bizzarri, Committing to vaccine R&D: a global science policy priority, Research Policy 33, 1657–1671
    3.Bone, Angie. Guthmann, Jean-Paul. Nicolau, Javier. Levy-Bruhl, Daniel. (2010), Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009–2010: Results of a national vaccination campaign, Vaccine 28, 8157–8161.
    4.Ciofi degli Atti, M.L. Rota, Maria Cristina. Bella, Antonino. Salmaso, Stefania. ICONA Study Gropu (2004), Do changes in policy affect vaccine coverage levels? Results of a national study to evaluate childhood vaccination coverageand reasons for missed vaccination in Italy, Vaccine 22, 4351–4357
    5.Davis, Matthew M. Butchart, Amy T. Scoleman, Margaret S. Singer, Dianne C. Wheeler, John R.C. Pok, Angela. Freed, Gary L.(2010) The expanding vaccine development pipeline, 1995–2008, Vaccine 28, 1353–1356
    6.DeRoeck, Denise. Deen, Jacqueline and Clements, John D. (2003), Policymakers’ views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries, Vaccine 22, 121–129 Gréco, Michel (2002), The future of vaccines: an industrial perspective, Vaccine 20, S101–S103
    7.GAVI’s PneumoADIP at Johns Hopkins (2006), GAVI Alliance Investment Case: Accelerating the Introduction of Pneumococcal Vaccines into GAVI-Eligible Countries. October 23
    8.Gre´co, Michel (2001), Key drivers behind the development of global vaccine market, Vaccine 19, 1606–1610
    9.Jadhava, Suresh. Datla, Mahima. Kreeftenberg, Hans. Hendriks, Jan (2008) The Developing Countries Vaccine Manufacturers’Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries, Vaccine 26,1611-1615
    10.Jadhav, Surensh S. Gautam, Manish. Gairola, Sunil. (2009), Emerging markets & emerging needs: Developing countries vaccine manufacturers’ perspective & its current status, Biologicals 37, 165-168
    11.Jürgen Sautter OleF, Olesen. JeremyBray, Ruxandr Draghia-Akli (2011), European Union vaccine research—An overview, Vaccine 29(39):6723-7
    12.Kimmana, Tjeerd G. Boot, Hein J. Berbers, Guy A. Vermeer-de Bondt, Patricia E. Ardine de Wit. Melker, Hester E. de. (2006), Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs, Vaccine 24, 4769–4778
    13.Lydon, P. Levine, R. Makinen, M. Brenzel, L. Mitchell, M. Milstien, J.B. Kamara, L. Landry, S. (2008), Introducing new vaccines in the poorest countries:What did we learn from the GAVI experience with financial, Vaccine 26, 6706–6716
    14.Mahoney, Richard T. Krattiger, Anatole. Clemens, John D., Curtiss III, Roy (2007), The introduction of new vaccines into developing countries IV: Global Access Strategies. Vaccine 25, 4003–4011
    15.Milstien, Julie. (2009), Challenges and potential solutions to innovative vaccine development for developing countries , 2nd Vaccine Global Congress, Boston 2008 Procedia in Vaccinology 1, 183–188
    16.Milstien, Julie B. Kaddar, Miloud. (2010), The role of emerging manufacturers in access to innovative vaccines of public health importance, Vaccine 28, 2115–2121.
    17.Munira, Syarifah Liza. Fritzten, Scott A. (2007), What influences government adoption of vaccines in developing countries? A policy process analysis Palanca-Tan, Rosalina (2008), The demand for a dengue vaccine: A contingent valuation survey in Metro Manila, Vaccine 26, 914—923
    18.Obaro, S.K. Palmer, A. (2003), Vaccines for children: policies, politics and poverty, Vaccine 21, 1423–1431
    19.Piso, B. Wild, C. (2009), Decision support in vaccination policies. Vaccine 27, 5923–5928
    20.Renub Research (2009), World Vaccines Market 2008-2013: FutureForecast, Critical Trends and Developments. Publisher: Renub Research Published: April, 2009
    21.Srinivas, Smita (2006), Industrial Development and Innovation: Some Lessons from Vaccine Procurement, World Development Vol. 34, No. 10, pp. 1742–1764.
    22.Stanberry, Lawrence R and Barrett, Alan D.T. (2009), Fundamental Aspects of Vaccinology, Vaccine Development Pathway, Vaccines for Biodefense and Emerging and Neglected Diseases, 45-55
    23.Taylor, Kate. Nguyen, Aurelia. Stephenne, Jean (2009), The need for new vaccines, Vaccine 27S, G3–G8
    24.Yin, Wesley (2008), Market incentives and pharmaceutical innovation, Journal of Health Economics 27, 1060–1077
    1.Audrey Wang (2011) Taiwan develops world’s first enterovirus 71 vaccine, Taiwan Today (01/11/2011). Retrived June 2011 from http://www.taiwantoday.tw/ct.asp?xitem=143057&ctnode=419&mp=9
    2.CBC News (2011), $425.9M pandemic flu contract awarded. Retrieved April 2011 from http://www.cbc.ca/news/canada/montreal/story/2011/03/25/flu-vaccine-pandemic-seasonal-health-canada.html
    3.China Bionews (2010), Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine, PRNewswire, Thursday, 30 December 2010, Retrieved June 2011 from http://news.chinabionews.com/biotech/437.html
    4.China Vaccine Focus 2011, 9 - 10 June, 2011 - Beijing, China, Retrieved June 2011 from http://www.giichinese.com.tw/conference/china-vaccine11/why.shtml
    5.Sanofi Pasteur corporate presentation slides kit 2010Oct
    6.Merck pipeline Feb 16, 2011, Retrieved April from http://www.merck.com/research/pipeline/home.html
    7.GSK pipeline Feb, 2011 Retrieved April from http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-2011.pdf
    8.Value of vaccine Sanofi pasteur, Retrieved April 2011 from http://www.sanofipasteur.com
    9.Pfizer pipeline Jan 27, 2010 Retrieved April 2011 from http://www.pfizer.com/home/
    1.王淑慧 (2003),公共政策、政治環境與企業經營,遠東技術學院企業管理系,遠東學報,第二十卷第四期,92年9月20日出版田珮 (2008),國家角色、科技產業政策與產業發展:歷經金融海嘯之台韓液晶顯示器產業競爭力分析,國立中央大學產業經濟研究所碩士論文
    2.丘昌泰 (2000),公共政策基礎篇,臺北巨流
    3.李允傑 (2011),政策管理與執行力: 跨域治理觀點,「國家文官學院」 T&D 飛訊,第111期,1-16 ,民國100年1月16日
    4.沈雅慧 (2010),台灣兒童侵襲性肺炎鏈球菌感染症流行病學的變化-疫苗政策的應用,國立成功大學公共衛生研究所碩士論文
    5.林佳瑩 (2009),製造公共需要:HPV疫苗的台灣經驗,臺灣大學,衛生政策與管理研究所碩士論文
    6.林思偕 (2010),新型流感(H1N1)疫苗事件的省思,長庚醫訊,第31卷,第2期,1-2
    7.許嘉伊 (2006),流感疫苗接種效益分析、風險評估與實行策略,台灣經濟研究月刊,第二十卷第三期,1-6
    8.許毓真 (2008),全球人用疫苗市場的黃金時期,生技醫藥產業智網,生物技術開發中心出版,2008/09/16
    9.許須美 (2003),台灣B型肝炎疫苗史,感染與疫苗,藝軒圖書出版社 2003/1/24出版
    10.徐慧玲、黃立民、李慶雲 (2003),疫苗接種實務,感染與疫苗,藝軒圖書出版社 2003/1/24出版
    11.涂醒哲 (2007),我國預防接種的政策制定與展望,台灣醫界,50 (10) ; 37-38
    12.陳明鶴 (2009),腸病毒71型疫苗願付價格—假設性市場評估法,國立中央大學產業經濟研究所碩士論文
    13.陳美霞 (2009),病毒無祖國,新流感與跨域治理,台灣民主季刊,第6卷,第二期:211-18
    14.陳恆鈞 (2002),治理互賴與政策執行,臺北商鼎詹中原 (1994),公共政策,台北:華泰出版社
    15.陳秀熙 (2003),疫苗經濟評估,預防接種的成本效益,感染與疫苗,藝軒圖書出版社 2003/1/24出版
    16.張朝卿 (2010),論公費疫苗預防接種受害救濟之法律性質、國家責任及其損害填補,國立成功大學科技法律研究所碩士論文
    17.張超群 (2005),2015 台灣生技醫藥產業發展機會與政策走向,科技法律透析,2005年5月
    18.黃秀美 (2008),疫苗小投資健康大保護,遠見雜誌,2008防疫特刊,2008 April
    19.蔡祈賢 (2011),從政策理管理論執行力,「國家文官學院」 T&D 飛訊,第110期,1-19,民國100年1月1日
    20.楊若英 (2007),國際疫苗論壇研討會報告,行政院衛生署藥物食品檢驗局,出國報告,8 月31 日
    21.趙雁南、蘇韋如 (2008),第九屆亞太地區疫苗學進階課程 9th International Advanced Course on Vaccinology for the Asia Pacific Regions,行政院衛生署疾病管制局,出國報告,8月19日
    22.劉定萍、張秀芳、李秉穎 (2008),考察韓國及香港目前推動之疫苗政策、預防接種受害救濟制度及作業模式,行政院衛生署疾病管制局疫苗中心出國報告,7月15日
    23.劉定萍 (2008),我國疫苗政策之展望,行政院衛生署疾病管制局
    24.劉定萍 (2008),我國疫苗新政策,我國疫苗新政策全國衛生行政會議簡報,傳染病防治組 疾病管制局疫苗中心,1月25日
    26.劉家齊 (2011),腸病毒71型疫苗進程說明,國家衛生研究院電子報,第 387 期,2011-01-06
    27.鄭雅文 (2010),從公衛社會歷史脈絡看H1N1疫苗政策,台灣人權促進會雜誌夏季號,206期,2010年9月1日
    28.鄭浩竹 (2009),台灣傳染病防治的國家創新體系?以疫苗發展為例,國立成功大學公共衛生研究所碩士論文
    29.鄭高奇 (2009),台灣的預防接種會更好,中國醫訊,防疫二三事,38-51
    30.鄭佩綺 (2010),全球疫苗未來發展趨勢,產業評析,ITIS 智網,2010/07/06 出版,檢索日期 March 2011 http://www.itis.org.tw/rptDetailFreeEPaper.screen?rptidno=608889492 accessed on March-30-201
    31.鍾添坤 (2008),疫苗發展作為台灣生技產業發展中主要領域中之一項─國光生技公司案例研究,國立政治大學國際經營管理英語碩士學程碩士論文
    32.謝文欽 (2010),Phacilitate Vaccine Forum Barcelona 2010 歐洲疫苗論壇國際研討會,行政院衛生署疾病管制局,出國報告,9月16日
    33.顏哲傑 (2005),衛生署疾病管制局第四組 台灣白喉、百日咳、破傷風疫苗接種策略之探討,疫情報導,11 月 25 日
    34.蘇益仁 (2008),新加坡世界疫苗會議後記—兼談台灣的疫苗產業發展 Impression of World Vaccine Congress Asia 2008 with reference to Vaccine Industrialization in Taiwan,國家衛生研究院電子報,第257期,2008-06-26
    35.蘇益仁、齊嘉鈺 (2007),台灣的疫苗產業政策National Strategy for Vaccine Development,國家衛生研究院電子報,第257期,2007-09-07
    36.中央研究院報告 (2011),因應新興感染性疾病政策建議書,No.005,100 年3月
    38.中國投資咨詢網 (2010),2011-2015年中國疫苗市場投資分析及前景預測報告。2010-11-2,檢索日期April 2011, http://big5.ocn.com.cn/free/201011/yimiao021149.htm
    40.行政院衛生署疾病管制局 (2000),預防接種的成本效益,疫情報導,368,民國 89 年 9 月 25 日
    41.行政院衛生署疾病管制局 (2010),我國因應流感大流行準備第二期計畫,行政院衛生署疾病管制局,2010年5月
    42.行政院衛生署疾病管制局 (2011),海峽兩岸醫藥衛生合作協議,檢索日期June 2011.http://www.doh.gov.tw/CHT2006/DM/DM2.aspx?now_fod_list_no=11643&class_no =478&level_no=1
    44.行政院衛生署傳染病防治諮詢委員會預防接種組,100年第1次會議會議紀錄 檢索日期April 2011 http://web.cdc.gov.tw/public/Attachment/16216544861.pdf
    45.產業技術白皮書 (2010),經濟部技術處
    46.科技政策研究與資訊中心 (2009),第三章科技活動與成就-應用研究與技術發展總論,STPI科技年鑑網Science and Technology year book,國家實驗研究院發行
    47.預防接種受害救濟審議委員會 (2011),H1N1申請及審議情況統計,行疾病管制局全球資訊網 檢索日期April 2011,http://web.cdc.gov.tw/np.asp?ctNode=4032&mp=190
    48.傳染病防治法,疾病管制局全球資訊網,檢索日期April 2011,http://www.cdc.gov.tw/lp.asp?ctNode=1807&CtUnit=991&BaseDSD=7&mp=1
    49.動物基因轉殖與疫苗發展技術教學資源中心 (2003),疫苗發展技術與實驗,教育部顧問室「生物技術科技教育改進計畫」出版
    4.行政院國家科學委員會 http://webl.nsc.gov.tw/#
    5.疾病管制局公關室(2011),2011全國防疫專家會議,防疫精英齊聚提供良策, 2011/3/26
    6.Gazettelabo. Fr (2010),疫苗逐漸成為製藥工業的存亡關鍵,國科會國際合作處駐法科技組,2010/11/28
    7.李樹人 (2008),全球27國推動公費子宮頸癌疫苗,金門做到了,醫藥論壇,聯合晚報,2008/12/24
    8.邱俐穎 (2011),流感死亡破百 累計達107例,中國時報,2011-03-08
    9.陳清芳 (2011),流感疫苗減量買 不全民接種,中央社,2011/5/24
    10.黃天如 (2011),肺炎鏈球菌疫苗納常規接種,中國時報,2011/04/01
    11.郭旭崧 (2010),疫苗公信力研討會,台灣應有製造疫苗產業,台灣時報,2010/01/03
    12.溫典寰 (2009),快速了解ECFA是什麼?簽與不簽的利弊又是什麼?天下雜誌:web only
    13.馬里蘭州銀泉 (2011),FDA批准第一種用於預防嬰幼兒腦膜炎球菌病的疫苗,可以使用於最小年齡9個月大的嬰幼兒,美通社,2011/4/23
    14.海峽醫藥生技風雲 (2011),全球疫苗戰況悄悄升溫,醫藥經濟報,2011/2/12
    15.財經諮詢小組 (2010),副總統主持總統府財經諮詢小組第27次會議,中華民國總統府,99年07月15日
    Description: 碩士
    Source URI: http://thesis.lib.nccu.edu.tw/record/#G0097359003
    Data Type: thesis
    Appears in Collections:[科技管理研究所] 學位論文

    Files in This Item:

    File SizeFormat
    900301.pdf3352KbAdobe PDF1741View/Open

    All items in 政大典藏 are protected by copyright, with all rights reserved.

    社群 sharing

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback